Wealthfront Advisers LLC Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Wealthfront Advisers LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 143.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,018 shares of the company's stock after acquiring an additional 18,268 shares during the quarter. Wealthfront Advisers LLC's holdings in Moderna were worth $879,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. OVERSEA CHINESE BANKING Corp Ltd boosted its stake in shares of Moderna by 73.5% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 40,772 shares of the company's stock valued at $1,156,000 after buying an additional 17,268 shares during the period. SBI Securities Co. Ltd. boosted its stake in shares of Moderna by 8.3% in the 1st quarter. SBI Securities Co. Ltd. now owns 19,561 shares of the company's stock valued at $555,000 after buying an additional 1,502 shares during the period. Apollon Wealth Management LLC boosted its stake in shares of Moderna by 47.8% in the 1st quarter. Apollon Wealth Management LLC now owns 9,549 shares of the company's stock valued at $271,000 after buying an additional 3,089 shares during the period. Signaturefd LLC boosted its stake in shares of Moderna by 36.9% in the 1st quarter. Signaturefd LLC now owns 4,954 shares of the company's stock valued at $140,000 after buying an additional 1,336 shares during the period. Finally, Edgestream Partners L.P. raised its stake in Moderna by 270.8% during the 1st quarter. Edgestream Partners L.P. now owns 97,961 shares of the company's stock worth $2,777,000 after acquiring an additional 71,544 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Morgan Stanley reduced their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. William Blair reiterated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. UBS Group reduced their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Barclays reissued an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Finally, Evercore ISI dropped their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $46.61.

Moderna Stock Performance

NASDAQ MRNA opened at $31.26 on Monday. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $125.68. The stock has a market capitalization of $12.09 billion, a PE ratio of -3.58 and a beta of 1.84. The stock has a 50-day simple moving average of $27.91 and a 200 day simple moving average of $30.77.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The firm's revenue was down 35.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.07) EPS. As a group, equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.